EADV 2025: Day 2 Recap

The second day of the European Academy of Dermatology and Venereology Congress is complete! Check out our day 2 recap below. To stay informed with the latest insights live from Paris, France, subscribe to receive our eNewsletters and follow Dermatology Times on LinkedIn, Facebook, and X.

Ruxolitinib Cream Shows Promise in Prurigo Nodularis at EADV 2025

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

A Paradigm Shift in Psoriasis Care: Almirall's POSITIVE Study and the Focus on Patient Well-Being

Almirall's POSITIVE study, presented at EADV 2025, prioritizes patient well-being, showcasing the holistic impact of advanced treatments.

Oral TNFR1 Inhibitor Balinatumab Shows Promise in Psoriasis

Balinatumab was generally well tolerated, with common adverse events such as nausea and arthralgia also observed in placebo groups.

OX40 Inhibition Delivers Significant Response in Treatment-Experienced AD

The ROCKET-SHUTTLE trial demonstrates that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

Galvokimig Achieves High EASI Scores in Pilot Study

Presented at EADV, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

LEO Pharma Presents Late-Breaking Results on Temtokibart for Atopic Dermatitis at EADV

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Study Finds Psoriasis Linked to Increased Risk of Age-Related Macular Degeneration

Findings from a large retrospective study presented at EADV 2025 suggest psoriasis significantly increases the risk of both wet and dry age-related macular degeneration.

Peter Lio, MD, at EADV 2025: Rethinking the Atopic Dermatitis Journey

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

Ascletis Presents Positive Phase 3 Data for Denifanstat in Moderate-to-Severe Acne

Denifanstat shows promising results in treating moderate to severe acne vulgaris, achieving significant efficacy and safety at the EADV Congress 2025.